NBI-31772 hydrate is a powerful inhibitor of the interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs). It acts as a nonpeptide ligand, effectively releasing bioactive IGF-I from the IGF-I/IGFBP-3 complex (Ki values for all six human subtypes range from 1-24 nM). This compound demonstrates significant anxiolytic and antidepressant-like effects [1] [2] [3].

NBI-31772 (5-100 μg; icv; immediately or at 1, 2, or, 3 hours after MCAO) at the time of ischemia onset also dose-dependently reduced infarct size, and the highest dose (100 μg) significantly reduced both total and cortical infarct volume [3]. Animal Model: Sprague-Dawley rats (subtemporal middle cerebral artery occlusion model, MCAO) [3] Dosage: 5-100 μg Administration: Icv; immediately or at 1, 2, or, 3 hours after MCAO Result: Resulted in a significant reduction of the total and cortical lesion volume.